Compare Amgen, Inc. (AMGN) vs Freeport-McMoRan Inc (FCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Freeport-McMoRan Inc — how do they compare? Amgen, Inc. trades at $358.08 (market cap $196.12B), while Freeport-McMoRan Inc trades at $61.34 (market cap $88.44B). The key difference: Amgen, Inc. is far larger — about 2.2× Freeport-McMoRan Inc's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | FCX | |
|---|---|---|
Market Cap | $196.12B | $88.44B |
Sector | Health | Basic Materials |
52-Week High | $388.16 | $71.73 |
52-Week Low | $271.18 | $35.34 |
Enterprise Value | $241.41B | $95.10B |
Dividend Yield | 2.77% | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
FCX trades at $61.52, up 1.69% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $0.60. Revenue growth is steady, and profitability metrics like a 10.34% net income margin and 14.7% ROE reflect operational strength. Recent news highlights FCX's role in the copper market, driven by AI and energy transition demand.
The outlook is positive due to robust copper demand and expansion projects, but risks include commodity price volatility and high debt. Analysts are bullish with a $73.35 consensus price target, implying 19% upside. Investors should weigh strong cash flows and dividend payments against cyclical industry exposure and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →
